Detection and staging of small cell lung carcinoma with a technetium- labeled monoclonal antibody

A comparison with standard staging methods

E. P. Balaban, B. S. Walker, J. V. Cox, R. P. Bordlee, D. Salk, P. G. Abrams, R. G. Sheehan, E. P. Frenkel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Tumor-associated radiolabeled monoclonal antibodies (MoAb) can detect neoplasms in a variety of settings. The authors conducted a study comparing the ability to detect and stage small cell lung carcinoma by using a Tc-99m labeled monoclonal antibody (NR-LU-10 Fab) (NeoRx Corp, Seattle, WA) with standard staging methods. Standard staging included a physical examination, chest x-ray, a battery of radionuclide scans and/or computerized tomographic studies (head, abdomen, and bone), and bone marrow examination. A total of 22 comparisons were performed in 17 patients (five patients had reevaluations after therapy). Fifty-four (74%) of the 73 lesions defined by standard staging were detected by the radiolabeled MoAb. Seven of eight patients (88%) classified by standard staging as having 'limited stage' disease on presentation were concordantly 'limited stage' by radioimmunoimaging. One patient deemed 'limited stage' by standard staging was correctly upstaged (bone marrow involvement) as a result of the radiolabeled MoAb. Two patients found to have extensive disease at diagnosis were characterized as 'limited stage' by the MoAb, for an overall staging accuracy of 0.88. Thirteen of 19 missed lesions were smaller than 2 cm (10 were smaller than 1 cm; 3 measured 1 to 2 cm). This comparative study shows that radioimmunoimaging by Tc-99m labeled NR-LU-10 Fab antibody is capable of complementing standard staging methods used in the evaluation of small cell lung carcinoma.

Original languageEnglish (US)
Pages (from-to)439-445
Number of pages7
JournalClinical Nuclear Medicine
Volume17
Issue number6
StatePublished - 1992

Fingerprint

Technetium
Small Cell Lung Carcinoma
Monoclonal Antibodies
Radioimmunodetection
Bone Marrow Examination
Radioisotopes
Abdomen
Physical Examination
Neoplasms
Thorax
Bone Marrow
Head
X-Rays
Bone and Bones

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Detection and staging of small cell lung carcinoma with a technetium- labeled monoclonal antibody : A comparison with standard staging methods. / Balaban, E. P.; Walker, B. S.; Cox, J. V.; Bordlee, R. P.; Salk, D.; Abrams, P. G.; Sheehan, R. G.; Frenkel, E. P.

In: Clinical Nuclear Medicine, Vol. 17, No. 6, 1992, p. 439-445.

Research output: Contribution to journalArticle

@article{1893da82225b45ba9def996fa47ad8de,
title = "Detection and staging of small cell lung carcinoma with a technetium- labeled monoclonal antibody: A comparison with standard staging methods",
abstract = "Tumor-associated radiolabeled monoclonal antibodies (MoAb) can detect neoplasms in a variety of settings. The authors conducted a study comparing the ability to detect and stage small cell lung carcinoma by using a Tc-99m labeled monoclonal antibody (NR-LU-10 Fab) (NeoRx Corp, Seattle, WA) with standard staging methods. Standard staging included a physical examination, chest x-ray, a battery of radionuclide scans and/or computerized tomographic studies (head, abdomen, and bone), and bone marrow examination. A total of 22 comparisons were performed in 17 patients (five patients had reevaluations after therapy). Fifty-four (74{\%}) of the 73 lesions defined by standard staging were detected by the radiolabeled MoAb. Seven of eight patients (88{\%}) classified by standard staging as having 'limited stage' disease on presentation were concordantly 'limited stage' by radioimmunoimaging. One patient deemed 'limited stage' by standard staging was correctly upstaged (bone marrow involvement) as a result of the radiolabeled MoAb. Two patients found to have extensive disease at diagnosis were characterized as 'limited stage' by the MoAb, for an overall staging accuracy of 0.88. Thirteen of 19 missed lesions were smaller than 2 cm (10 were smaller than 1 cm; 3 measured 1 to 2 cm). This comparative study shows that radioimmunoimaging by Tc-99m labeled NR-LU-10 Fab antibody is capable of complementing standard staging methods used in the evaluation of small cell lung carcinoma.",
author = "Balaban, {E. P.} and Walker, {B. S.} and Cox, {J. V.} and Bordlee, {R. P.} and D. Salk and Abrams, {P. G.} and Sheehan, {R. G.} and Frenkel, {E. P.}",
year = "1992",
language = "English (US)",
volume = "17",
pages = "439--445",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Detection and staging of small cell lung carcinoma with a technetium- labeled monoclonal antibody

T2 - A comparison with standard staging methods

AU - Balaban, E. P.

AU - Walker, B. S.

AU - Cox, J. V.

AU - Bordlee, R. P.

AU - Salk, D.

AU - Abrams, P. G.

AU - Sheehan, R. G.

AU - Frenkel, E. P.

PY - 1992

Y1 - 1992

N2 - Tumor-associated radiolabeled monoclonal antibodies (MoAb) can detect neoplasms in a variety of settings. The authors conducted a study comparing the ability to detect and stage small cell lung carcinoma by using a Tc-99m labeled monoclonal antibody (NR-LU-10 Fab) (NeoRx Corp, Seattle, WA) with standard staging methods. Standard staging included a physical examination, chest x-ray, a battery of radionuclide scans and/or computerized tomographic studies (head, abdomen, and bone), and bone marrow examination. A total of 22 comparisons were performed in 17 patients (five patients had reevaluations after therapy). Fifty-four (74%) of the 73 lesions defined by standard staging were detected by the radiolabeled MoAb. Seven of eight patients (88%) classified by standard staging as having 'limited stage' disease on presentation were concordantly 'limited stage' by radioimmunoimaging. One patient deemed 'limited stage' by standard staging was correctly upstaged (bone marrow involvement) as a result of the radiolabeled MoAb. Two patients found to have extensive disease at diagnosis were characterized as 'limited stage' by the MoAb, for an overall staging accuracy of 0.88. Thirteen of 19 missed lesions were smaller than 2 cm (10 were smaller than 1 cm; 3 measured 1 to 2 cm). This comparative study shows that radioimmunoimaging by Tc-99m labeled NR-LU-10 Fab antibody is capable of complementing standard staging methods used in the evaluation of small cell lung carcinoma.

AB - Tumor-associated radiolabeled monoclonal antibodies (MoAb) can detect neoplasms in a variety of settings. The authors conducted a study comparing the ability to detect and stage small cell lung carcinoma by using a Tc-99m labeled monoclonal antibody (NR-LU-10 Fab) (NeoRx Corp, Seattle, WA) with standard staging methods. Standard staging included a physical examination, chest x-ray, a battery of radionuclide scans and/or computerized tomographic studies (head, abdomen, and bone), and bone marrow examination. A total of 22 comparisons were performed in 17 patients (five patients had reevaluations after therapy). Fifty-four (74%) of the 73 lesions defined by standard staging were detected by the radiolabeled MoAb. Seven of eight patients (88%) classified by standard staging as having 'limited stage' disease on presentation were concordantly 'limited stage' by radioimmunoimaging. One patient deemed 'limited stage' by standard staging was correctly upstaged (bone marrow involvement) as a result of the radiolabeled MoAb. Two patients found to have extensive disease at diagnosis were characterized as 'limited stage' by the MoAb, for an overall staging accuracy of 0.88. Thirteen of 19 missed lesions were smaller than 2 cm (10 were smaller than 1 cm; 3 measured 1 to 2 cm). This comparative study shows that radioimmunoimaging by Tc-99m labeled NR-LU-10 Fab antibody is capable of complementing standard staging methods used in the evaluation of small cell lung carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0026780409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026780409&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 439

EP - 445

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 6

ER -